Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
131 hedge funds and large institutions have $1.42B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2018 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 20 closing their positions.
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
81% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $7.89M
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
29% more capital invested
Capital invested by funds: $1.1B → $1.42B (+$317M)
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
10% more funds holding
Funds holding: 119 → 131 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$83.1M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$29.4M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$24.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$37.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$11.2M |
| 3 |
VMI
VHCP Management II
New York
|
-$10M |
| 4 |
DM
Deerfield Management
New York
|
-$8.97M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$8.52M |
BHVN Hedge Fund Activity: Q4 2018 in Review
131 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q4 2018, worth a combined $1.42B — up 29% from $1.1B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new BHVN positions and 20 closed out — a net gain of 12 holders — while 45 added to existing stakes and 36 trimmed.
The largest buyer was Stifel Financial, adding an estimated $83.1M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $37.2M sold.
- 131 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q4 2018, up from 119 in Q3 2018.
- Funds reported $1.42B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q4 2018, up 29% quarter-over-quarter.
- 32 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q4 2018 and 20 closed out, a net change of +12 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q4 2018 was Stifel Financial, an estimated $83.1M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q4 2018 was Perceptive Advisors, an estimated $37.2M sold.
Based on aggregated 13F filings for Q4 2018.